kidney Wilms tumor

Summary

kidney Wilms tumor (MONDO:0019004) is a cancer (an umbrella term covering 8 Mondo subtypes) with 3 cohort genes (1 CIViC-evidence somatic driver) and 90 clinical trials. Top therapeutic interventions include dactinomycin, larotrectinib, and cabozantinib.

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Umbrella term: 8 Mondo subtypes
• Cohort genes: 3
• Phenotypes (HPO): 27
• Clinical trials: 90

Clinical features

Epidemiology

Prevalence records

27 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.14	Europe	Validated
Lifetime Prevalence	1-9 / 100 000	3.65	Europe	Validated
Point prevalence	1-9 / 100 000		Europe	Validated
Prevalence at birth	1-5 / 10 000	10	Europe	Validated
Annual incidence	1-9 / 1 000 000	0.144	United Kingdom	Validated
Annual incidence	<1 / 1 000 000	0.072	Bulgaria	Validated
Annual incidence	<1 / 1 000 000	0.006	Czech Republic	Validated
Annual incidence	<1 / 1 000 000	0.089	Germany	Validated
Annual incidence	<1 / 1 000 000	0.043	Iceland	Validated
Annual incidence	<1 / 1 000 000	0.065	Latvia	Validated
Annual incidence	<1 / 1 000 000	0.066	Portugal	Validated
Annual incidence	1-9 / 1 000 000	0.121	Austria	Validated
Annual incidence	1-9 / 1 000 000	0.195	Belgium	Validated
Annual incidence	1-9 / 1 000 000	0.155	Croatia	Validated
Annual incidence	1-9 / 1 000 000	0.139	Estonia	Validated
Annual incidence	1-9 / 1 000 000	0.158	Finland	Validated
Annual incidence	1-9 / 1 000 000	0.17	Ireland	Validated
Annual incidence	1-9 / 1 000 000	0.111	Italy	Validated
Annual incidence	1-9 / 1 000 000	0.12	Lithuania	Validated
Annual incidence	1-9 / 1 000 000	0.157	Malta	Validated

Signs & symptoms

Clinical features (HPO)

27 HPO clinical features (Orphanet curated; top 27 by frequency):

HPO ID	Term	Frequency
HP:0002664	Neoplasm	Very frequent (80-99%)
HP:0002667	Nephroblastoma	Very frequent (80-99%)
HP:0031500	Abdominal mass	Very frequent (80-99%)
HP:0002027	Abdominal pain	Frequent (30-79%)
HP:0005580	Duplication of renal pelvis	Frequent (30-79%)
HP:0012587	Macroscopic hematuria	Frequent (30-79%)
HP:0000028	Cryptorchidism	Occasional (5-29%)
HP:0000047	Hypospadias	Occasional (5-29%)
HP:0000085	Horseshoe kidney	Occasional (5-29%)
HP:0000086	Ectopic kidney	Occasional (5-29%)
HP:0000526	Aniridia	Occasional (5-29%)
HP:0000822	Hypertension	Occasional (5-29%)
HP:0001528	Hemihypertrophy	Occasional (5-29%)
HP:0001824	Weight loss	Occasional (5-29%)
HP:0001901	Polycythemia	Occasional (5-29%)
HP:0001903	Anemia	Occasional (5-29%)
HP:0001945	Fever	Occasional (5-29%)
HP:0002716	Lymphadenopathy	Occasional (5-29%)
HP:0002896	Neoplasm of the liver	Occasional (5-29%)
HP:0002907	Microscopic hematuria	Occasional (5-29%)
HP:0003072	Hypercalcemia	Occasional (5-29%)
HP:0008330	Reduced von Willebrand factor activity	Occasional (5-29%)
HP:0012871	Varicocele	Occasional (5-29%)
HP:0031105	Abnormal uterus morphology	Occasional (5-29%)
HP:0033834	Malaise	Occasional (5-29%)
HP:0100526	Neoplasm of the lung	Occasional (5-29%)
HP:0002094	Dyspnea	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	kidney Wilms tumor
Mondo ID	MONDO:0019004
Orphanet	654
DOID	DOID:2154, DOID:5176
NCIT	C40407
SNOMED CT	302849000
GARD	0007892
MedDRA	10029145
NORD	1855
Is cancer (heuristic)	yes

Also known as: adult nephroblastoma · adult renal Wilms’ tumour · childhood renal Wilms tumor · childhood renal Wilms tumour · childhood renal Wilms’ cancer · embryonal nephroma · kidney Wilms tumor · nephroblastoma · nephroblastoma, malignant · nonanaplastic renal Wilm’s tumor · nonanaplastic renal Wilm’s tumour · renal embryonic tumor · renal embryonic tumour · renal Wilms tumor · renal Wilms tumour · renal Wilms’ tumor · Wilms tumor · Wilms tumor of the kidney · Wilms tumour · Wilms tumour of the kidney (+5 more)

Data availability: 2 GenCC gene-disease records · 59 cell lines · 8 intOGen driver records.

Disease family

An umbrella term covering 8 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant urinary system neoplasm › kidney cancer › kidney Wilms tumor

Related subtypes (7): kidney sarcoma, mesoblastic nephroma, renal carcinoma, Graham-Boyle-Troxell syndrome, malignant mixed epithelial stromal tumor of the kidney, childhood malignant kidney neoplasm, malignant renal pelvis neoplasm

Subtypes (8): nonanaplastic kidney Wilms tumor, metachronous kidney Wilms’ tumor, mixed cell type kidney Wilms’ tumor, blastema predominant kidney Wilms tumor, epithelial predominant Wilms’ tumor, stromal predominant kidney Wilms tumor, adult kidney Wilms tumor, childhood kidney Wilms tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 12 · Orphanet: 23 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
TP53	LoF	ACC,ALL,AML,ANGS,ANSC,BCC,BL,BLADDER,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,CHRCC,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,EGC,ES,ESCA,ESCC,GB,GBC,GBM,GIST,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LMS,LNM,LUAD,LUSC,MBL,MEL,MLYM,MT,NBL,NETNOS,NHL,NPC,NSCLC,OS,OVT,PAAD,PANCREAS,PAST,PCM,PLMESO,PRAD,PRCC,PROSTATE,RCC,READ,SACA,SARCNOS,SCLC,SIC,SKCM,SKIN,SOFT_TISSUE,STAD,STOMACH,THYM,UCEC,UCS,UTUC,VULVA,WDTC,WT	CIViC #45

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
TRIM28	Definitive	Autosomal dominant	childhood kidney Wilms tumor	2
TRIP13	Supportive	Autosomal dominant	kidney Wilms tumor	10

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TP53	Orphanet:1333	Familial pancreatic carcinoma
TP53	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
TP53	Orphanet:1501	Adrenocortical carcinoma
TP53	Orphanet:210159	Adult hepatocellular carcinoma
TP53	Orphanet:251576	Gliosarcoma
TP53	Orphanet:251579	Giant cell glioblastoma
TP53	Orphanet:251899	Choroid plexus carcinoma
TP53	Orphanet:2807	Papilloma of choroid plexus
TP53	Orphanet:293199	Pleomorphic rhabdomyosarcoma
TP53	Orphanet:3318	Essential thrombocythemia
TP53	Orphanet:524	Li-Fraumeni syndrome
TP53	Orphanet:52688	Myelodysplastic syndrome
TP53	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
TP53	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
TP53	Orphanet:668	Osteosarcoma
TP53	Orphanet:67038	B-cell chronic lymphocytic leukemia
TP53	Orphanet:70573	Small cell lung cancer
TP53	Orphanet:96253	Cushing disease
TP53	Orphanet:99756	Alveolar rhabdomyosarcoma
TP53	Orphanet:99757	Embryonal rhabdomyosarcoma
TRIP13	Orphanet:1052	Mosaic variegated aneuploidy syndrome
TRIP13	Orphanet:654	Nephroblastoma
TRIM28	Orphanet:654	Nephroblastoma

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TP53	HGNC:11998	ENSG00000141510	P04637	Cellular tumor antigen p53	civic_evidence
TRIP13	HGNC:12307	ENSG00000071539	Q15645	Pachytene checkpoint protein 2 homolog	gencc
TRIM28	HGNC:16384	ENSG00000130726	Q13263	Transcription intermediary factor 1-beta	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TP53	Cellular tumor antigen p53	Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence.
TRIP13	Pachytene checkpoint protein 2 homolog	Plays a key role in chromosome recombination and chromosome structure development during meiosis.
TRIM28	Transcription intermediary factor 1-beta	Nuclear corepressor for KRAB domain-containing zinc finger proteins (KRAB-ZFPs).

Protein-family classification

Druggable: 0 · Difficult: 2 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	2	5.5×	0.081
Other/Unknown	1	0.6×	0.914

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TP53	Transcription factor	no		p53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn
TRIP13	Other/Unknown	no		ClpA/B, AAA+_ATPase, ATPase_AAA_core
TRIM28	Transcription factor	no		Znf_B-box, Bromodomain, Znf_RING

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ventricular zone	2
ganglionic eminence	1
tendon of biceps brachii	1
bronchial epithelial cell	1
bronchus	1
epithelium of bronchus	1
left testis	1
right testis	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TP53	223	ubiquitous	marker	ventricular zone, ganglionic eminence, tendon of biceps brachii
TRIP13	212	ubiquitous	marker	bronchial epithelial cell, epithelium of bronchus, bronchus
TRIM28	145	ubiquitous	marker	left testis, right testis, ventricular zone

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TP53	22,736
TRIM28	8,167
TRIP13	4,676

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TP53	P04637	313
TRIM28	Q13263	10
TRIP13	Q15645	6

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 62. Enrichment computed across 3 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Loss of function of TP53 in cancer due to loss of tetramerization ability	1	5710.0×	0.011	TP53
Regulation of TP53 Expression	1	2855.0×	0.011	TP53
Transcriptional activation of cell cycle inhibitor p21	1	1427.5×	0.011	TP53
Activation of NOXA and translocation to mitochondria	1	951.7×	0.011	TP53
RUNX3 regulates CDKN1A transcription	1	815.7×	0.011	TP53
PI5P Regulates TP53 Acetylation	1	634.4×	0.011	TP53
Activation of PUMA and translocation to mitochondria	1	571.0×	0.011	TP53
TP53 Regulates Transcription of Caspase Activators and Caspases	1	475.8×	0.011	TP53
TP53 Regulates Transcription of Death Receptors and Ligands	1	475.8×	0.011	TP53
Urea cycle	1	439.2×	0.011	TP53
Regulation of TP53 Activity through Association with Co-factors	1	407.9×	0.011	TP53
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	1	380.7×	0.011	TP53
Stabilization of p53	1	380.7×	0.011	TP53
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	1	356.9×	0.011	TP53
Formation of Senescence-Associated Heterochromatin Foci (SAHF)	1	335.9×	0.011	TP53
Zygotic genome activation (ZGA)	1	335.9×	0.011	TP53
Regulation of NF-kappa B signaling	1	317.2×	0.011	TP53
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	1	300.5×	0.011	TP53
SUMOylation of transcription factors	1	285.5×	0.011	TP53
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	1	271.9×	0.011	TP53
Regulation of TP53 Activity through Methylation	1	271.9×	0.011	TP53
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain	1	259.6×	0.011	TP53
Regulation of TP53 Activity through Acetylation	1	228.4×	0.012	TP53
Pyroptosis	1	211.5×	0.012	TP53
Regulation of endogenous retroelements	1	184.2×	0.013	TRIM28
Oncogene Induced Senescence	1	167.9×	0.014	TP53
HCMV Infection	1	163.1×	0.014	TRIM28
Association of TriC/CCT with target proteins during biosynthesis	1	146.4×	0.015	TP53
Regulation of TP53 Degradation	1	146.4×	0.015	TP53
Ovarian tumor domain proteases	1	139.3×	0.015	TP53

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
negative regulation of helicase activity	1	5617.3×	0.005	TP53
cellular response to actinomycin D	1	5617.3×	0.005	TP53
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	1	5617.3×	0.005	TP53
negative regulation of G1 to G0 transition	1	5617.3×	0.005	TP53
positive regulation of mitochondrial membrane permeability	1	2808.7×	0.005	TP53
oligodendrocyte apoptotic process	1	2808.7×	0.005	TP53
negative regulation of glucose catabolic process to lactate via pyruvate	1	2808.7×	0.005	TP53
negative regulation of pentose-phosphate shunt	1	2808.7×	0.005	TP53
obsolete homolactic fermentation	1	1872.4×	0.005	TP53
meiotic recombination checkpoint signaling	1	1872.4×	0.005	TRIP13
signal transduction by p53 class mediator	1	1872.4×	0.005	TP53
negative regulation of miRNA processing	1	1872.4×	0.005	TP53
intrinsic apoptotic signaling pathway in response to hypoxia	1	1872.4×	0.005	TP53
regulation of fibroblast apoptotic process	1	1872.4×	0.005	TP53
T cell proliferation involved in immune response	1	1404.3×	0.005	TP53
positive regulation of programmed necrotic cell death	1	1404.3×	0.005	TP53
oxidative stress-induced premature senescence	1	1404.3×	0.005	TP53
B cell lineage commitment	1	1123.5×	0.005	TP53
T cell lineage commitment	1	1123.5×	0.005	TP53
mRNA transcription	1	1123.5×	0.005	TP53
positive regulation of RNA polymerase II transcription preinitiation complex assembly	1	1123.5×	0.005	TP53
convergent extension involved in axis elongation	1	1123.5×	0.005	TRIM28
embryonic placenta morphogenesis	1	1123.5×	0.005	TRIM28
positive regulation of thymocyte apoptotic process	1	1123.5×	0.005	TP53
cellular response to UV-C	1	1123.5×	0.005	TP53
double-strand break repair	2	135.4×	0.005	TP53, TRIP13
regulation of mitochondrial membrane permeability involved in apoptotic process	1	936.2×	0.006	TP53
viral process	1	802.5×	0.006	TP53
mitochondrial DNA repair	1	802.5×	0.006	TP53
regulation of cell cycle G2/M phase transition	1	802.5×	0.006	TP53

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 2

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TP53	NITROFURANTOIN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TP53	196	4
TRIP13	0	0
TRIM28	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53
AMIODARONE HYDROCHLORIDE	4	TP53
FURAZOLIDONE	4	TP53
AMOXAPINE	4	TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
TP53	869	Binding:775, ADMET:83, Functional:10, Toxicity:1
TRIM28	19	Binding:19
TRIP13	9	Binding:9

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TP53	869

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53
AMIODARONE HYDROCHLORIDE	4	TP53
FURAZOLIDONE	4	TP53
AMOXAPINE	4	TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	TP53
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	TRIP13, TRIM28

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
TRIP13	9	—
TRIM28	19	—

Clinical trials & evidence

Clinical trials

Clinical trials: 90.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	28
Not specified	28
PHASE1	25
PHASE1/PHASE2	4
PHASE3	3
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00336531	PHASE4	COMPLETED	Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
NCT00352534	PHASE3	ACTIVE_NOT_RECRUITING	Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms’ Tumor
NCT00379340	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms’ Tumor
NCT00945009	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
NCT02867592	PHASE2	ACTIVE_NOT_RECRUITING	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT03155620	PHASE2	ACTIVE_NOT_RECRUITING	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03210714	PHASE2	ACTIVE_NOT_RECRUITING	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
NCT03213652	PHASE2	ACTIVE_NOT_RECRUITING	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213704	PHASE2	ACTIVE_NOT_RECRUITING	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCT03698994	PHASE2	ACTIVE_NOT_RECRUITING	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555	PHASE2	ACTIVE_NOT_RECRUITING	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04284774	PHASE2	ACTIVE_NOT_RECRUITING	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888	PHASE2	ACTIVE_NOT_RECRUITING	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04322318	PHASE2	RECRUITING	A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04851119	PHASE1/PHASE2	RECRUITING	Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT04901702	PHASE1/PHASE2	RECRUITING	Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
NCT04968990	PHASE2	RECRUITING	Treatment of Newly Diagnosed Patient’s With Wilm’s Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
NCT05384821	PHASE1/PHASE2	RECRUITING	Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
NCT05985161	PHASE2	RECRUITING	A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
NCT00001509	PHASE2	COMPLETED	A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms’ Tumor
NCT00038207	PHASE2	COMPLETED	Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
NCT00141765	PHASE2	COMPLETED	Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
NCT00187031	PHASE2	COMPLETED	A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor
NCT00335556	PHASE2	COMPLETED	Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
NCT01095926	PHASE2	COMPLETED	Pharmacokinetic Study of Doxorubicin in Children With Cancer
NCT02452554	PHASE2	COMPLETED	Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
NCT02581384	PHASE1/PHASE2	TERMINATED	Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors
NCT02624388	PHASE2	TERMINATED	Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
NCT02689336	PHASE2	WITHDRAWN	Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
NCT03213665	PHASE2	COMPLETED	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
NCT03213678	PHASE2	COMPLETED	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
NCT03220035	PHASE2	COMPLETED	Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
NCT03233204	PHASE2	COMPLETED	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
NCT03526250	PHASE2	COMPLETED	Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
NCT04791228	PHASE2	WITHDRAWN	A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
NCT05302921	PHASE2	COMPLETED	Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
NCT03618381	PHASE1	ACTIVE_NOT_RECRUITING	EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
NCT04308330	PHASE1	RECRUITING	Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
NCT04377932	PHASE1	ACTIVE_NOT_RECRUITING	Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
NCT04483778	PHASE1	ACTIVE_NOT_RECRUITING	B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DACTINOMYCIN	4	4
LAROTRECTINIB	4	4
CABOZANTINIB	4	3
ENSARTINIB	4	2
ERDAFITINIB	4	2
IVOSIDENIB	4	2
SELPERCATINIB	4	2
SELUMETINIB	4	2
TAZEMETOSTAT	4	2
VEMURAFENIB	4	2
ITRACONAZOLE	4	1
PEGFILGRASTIM	4	1
SELINEXOR	4	1
TALAZOPARIB	4	1
TOPOTECAN	4	1
TIPIFARNIB	3	2
BECOTATUG VEDOTIN	3	1
DOCIPARSTAT SODIUM	3	1
GALINPEPIMUT-S	3	1
TARIQUIDAR	3	1
SAMOTOLISIB	2	2
ULIXERTINIB	2	2
ENOBLITUZUMAB	2	1
GENISTEIN	2	1
LORVOTUZUMAB MERTANSINE	2	1
TEGAVIVINT	2	1
CHEMBL4748391	0	4
CHEMBL3415553	0	2
CHEMBL4209555	0	2
CHEMBL5398431	0	2